Adaptive Minimax-Regret Treatment Choice, With Application To Drug Approval
AbstractSuppose that there are two treatments for a condition. One is the status quo, whose properties are known from experience and the other is an innovation, whose properties are not known initially. A new cohort of persons presents itself each period and a planner must choose how to treat this cohort. When facing situations of this kind, it has become common to commission randomized trials of limited duration to learn about the innovation. Rather than wait for the outcomes of interest to unfold over time, surrogate outcomes that can be observed early on are used to judge the success of the innovation. A close approximation to this process is institutionalized in the drug approval protocol of the U. S. Food and Drug Administration. This paper brings welfare-economic and decision-theoretic thinking to bear on the problem of treatment choice, with application to drug approval. I introduce the adaptive minimax-regret (AMR) rule, which applies to each cohort the minimax-regret criterion using the knowledge of treatment response available at the time of treatment. The result is a fractional treatment allocation whenever the available knowledge does not suffice to determine which treatment is better. The rule is adaptive because, as knowledge of treatment response accumulates, successive cohorts are allocated differently across the two treatments. I use the AMR idea to suggest an adaptive drug approval process that permits partial marketing of new drugs while scientifically appropriate long-term clinical trials are underway. The stronger the evidence on health outcomes of interest, the more treatment would be permitted, with a definitive approval decision eventually made when sufficient evidence has accumulated.
Download InfoIf you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.
Bibliographic InfoPaper provided by National Bureau of Economic Research, Inc in its series NBER Working Papers with number 13312.
Date of creation: Aug 2007
Date of revision:
Note: HC HE PE
Contact details of provider:
Postal: National Bureau of Economic Research, 1050 Massachusetts Avenue Cambridge, MA 02138, U.S.A.
Web page: http://www.nber.org
More information through EDIRC
Other versions of this item:
- Charles F Manski, 2007. "Adaptive Minimax-Regret Treatment Choice, with Application to Drug Approval," Levine's Working Paper Archive 122247000000001404, David K. Levine.
- D63 - Microeconomics - - Welfare Economics - - - Equity, Justice, Inequality, and Other Normative Criteria and Measurement
- I18 - Health, Education, and Welfare - - Health - - - Government Policy; Regulation; Public Health
This paper has been announced in the following NEP Reports:
Please report citation or reference errors to , or , if you are the registered author of the cited work, log in to your RePEc Author Service profile, click on "citations" and make appropriate adjustments.:
- Manski, Charles F., 2007. "Minimax-regret treatment choice with missing outcome data," Journal of Econometrics, Elsevier, vol. 139(1), pages 105-115, July.
- Stoye, Jörg, 2009. "Minimax regret treatment choice with finite samples," Journal of Econometrics, Elsevier, vol. 151(1), pages 70-81, July.
If references are entirely missing, you can add them using this form.